Company Filing History:
Years Active: 2013-2020
Title: Antonin DeFougerolles: Innovator in RNA Therapeutics
Introduction
Antonin DeFougerolles is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of RNA therapeutics, holding a total of 4 patents. His work focuses on innovative methods to inhibit gene expression, particularly in the context of cancer treatment.
Latest Patents
Among his latest patents is a groundbreaking invention titled "Compositions and methods for inhibiting expression of CD274/PD-L1 gene." This invention relates to double-stranded ribonucleic acid (dsRNA) compositions that specifically target the CD274/PD-L1 gene. The methods developed using these dsRNA compositions aim to effectively inhibit the expression of CD274/PD-L1, which plays a crucial role in immune evasion by tumors.
Career Highlights
Antonin DeFougerolles is currently associated with Alnylam Pharmaceuticals, Inc., a leading company in the field of RNA interference. His work at Alnylam has positioned him as a key player in the development of novel therapeutic strategies that leverage RNA technology.
Collaborations
He has collaborated with notable colleagues such as Tatiana Novobrantseva and Brian R Bettencourt, contributing to the advancement of RNA-based therapies.
Conclusion
Antonin DeFougerolles continues to be a driving force in the field of RNA therapeutics, with his innovative patents paving the way for new treatment options in cancer therapy. His contributions are vital to the ongoing research and development in this promising area of medicine.